Background
==========

Triglycerides are a key fetal fuel in pregnancy. Triglyceride concentrations are raised in pregnancy due to the overproduction of triglyceride rich very low-density lipoprotein (VLDL) cholesterol \[[@B1]\]. Pregnancy also elevates total and low-density lipoprotein (LDL) cholesterols \[[@B2]\] and lowers high-density lipoprotein (HDL) cholesterol \[[@B1]\]. Triglyceride concentrations increase gradually with the duration of pregnancy with significant increases during the second trimester \[[@B2]\]. Triglyceride and cholesterol concentrations return to pre-pregnant concentrations 20--24 weeks post partum \[[@B2]\], with a rapid reduction in triglycerides and cholesterol in breast-feeding mothers compared to mothers where lactation was never established \[[@B3]\].

Triglyceride and cholesterol concentrations are under strong genetic control. Variants in several genes, including, *ApoE*\[[@B1]\], *LPL*\[[@B1]\], *LDL receptor*\[[@B4]\], *Apolipoprotein CIII*(*ApoCIII*) \[[@B5]\], *Apolipoprotein AIV (ApoAIV)*\[[@B5]\] and, recently *ApoAV*\[[@B6]\] are associated with altered triglyceride and cholesterol concentrations \[[@B7]\]. Despite this, little is known about how these variants alter lipid profiles in pregnancy. In one study of 250 pregnant females from a number of ethnic groups, the genes encoding *LPL*(S447X and N291S) and *ApoE*(E2 allele) are associated with altered triglyceride and HDL-cholesterol concentrations in pregnancy \[[@B1]\].

High triglyceride concentrations in pregnancy can result in acute pancreatitis \[[@B8]\] and are associated with pre-eclampsia \[[@B9]\]. In addition to these implications for maternal health, maternal triglyceride concentrations are correlated with offspring birth weight. This correlation is independent of maternal pre-pregnant Body Mass Index (BMI), maternal weight gain, fasting glucose, gender and gestational age \[[@B10]\].

Common variation in the *ApoAV*gene has recently been shown to have one of the largest effects on triglyceride concentrations in the normal population. *ApoAV*was recently discovered in the *ApoAI/CIII*and *AIV*gene cluster using comparative genomics of human and mouse genomes \[[@B6]\]. Studies on transgenic and knockout mice showed that *ApoAV*is a key regulator of triglyceride concentrations in mice. In man, two haplotypes of the *ApoAV*gene, each of \~6.0% frequency in caucasians and defined by the C and W alleles of the -1131T\>C and S19W single nucleotide polymorphisms (SNP), are associated with increased triglyceride concentrations. Male carriers of one or two copies of the -1131C and 19W have triglyceride concentrations \~40.0% higher than subjects homozygous for the -1131T and 19S alleles \[[@B11]\]. There is less data available in women, but, a study of 442 caucasian women from the Dallas Heart Disease Prevention Project (DHDPP) showed an increase of 22.0% in carriers of either the -1131C or 19W haplotypes \[[@B11]\]. In addition to altering triglyceride concentrations, *ApoAV*variants have been associated with VLDL-cholesterol (P = \<0.001), but not altered HDL-cholesterol or LDL-cholesterol concentrations \[[@B11]\]. Non-pregnant caucasian women were shown to have triglycerides that were 23.0% (17.4% -- 36.6%) lower than caucasian males \[[@B11]\], p \< 0.05.

The -1131C allele raises triglyceride concentrations in a variety of dyslipidaemic conditions such as hyperlipidaemia, hypoalphalipoproteinaemia and hyperalphalipoproteinaemia from the University of California, San Francisco (UCSF) Genomic Resource in Arteriosclerosis \[[@B7]\].

The chemical properties of Apolipoprotein AV indicate that it may retard triglyceride-rich particle assembly and may function intracellularly to modulate hepatic Very Low Density Lipoprotein (VLDL) synthesis and/or secretion \[[@B12]\]. The Apolipoprotein AV gene is only expressed in the liver and has a very low plasma concentration. *ApoAV*may therefore affect plasma triglyceride levels by modulating hepatic VLDL assembly and secretion, rather than the intravascular metabolism of triglyceride-rich lipoproteins \[[@B12]\]. The -1131T\>C polymorphism is in the promoter region and may therefore affect transcription of the *ApoAV*gene. The S19W polymorphism changes the amino acid serine to a tryptophan at codon 19. This change could alter the secondary structure of the protein and alter protein folding, thus altering the function of the protein.

The role of *ApoAV*gene variants in regulating triglyceride concentrations in pregnancy is not known. To gain a better understanding of the genetic control of triglycerides in pregnancy and potential effects on fetal growth we have examined the role of the variants -1131T\>C and S19W in the *ApoAV*gene in caucasian pregnant women and their offspring. We have shown that two common variants in the *ApoAV*gene alter triglycerides in pregnancy by 11.0% (1.5% to 22.2%) and 16.2% (7.6% to 25.9%).

Results
=======

Triglyceride concentrations in 483 pregnant females (2.01 mmol/l (1.96 -- 2.06)) were higher than those in their male partners (1.34 mmol/l (1.28 -- 1.39), p value of \<0.001).

Both Single Nucleotide Polymorphisms (SNPs) were in Hardy Weinberg Equilibrium. The frequencies of the two rare alleles were 6.7% for -1131T\>C and 4.9% for S19W. Nine point seven percent of subjects are carriers of at least one -1131C allele and 13.4% are carriers of at least one 19W allele with 0.6% carrying both a -1131C and a 19W allele. We did not observe any significant LD between the two variants, D\' = 0.33; p \>0.5.

The -1131T\>C and S19W *ApoAV*variants alter triglyceride concentrations in pregnancy
-------------------------------------------------------------------------------------

Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"} show the effect on maternal anthropometry and biochemistry for -1131T\>C and S19W respectively. Each of the two *ApoAV*variants was associated with altered triglyceride concentrations in pregnancy. The two SNPs increased triglycerides concentrations by a similar magnitude of effect, the -1131C showed a 11.0% increase (from 1.98 mmol/l (1.92 -- 2.04) to 2.20 mmol/l (2.01 -- 2.42), p = 0.035), and 19W a 16.2% increase (from 1.97 mmol/l (1.91 -- 2.03) to 2.29 mmol/l (2.12 -- 2.48), p \< 0.001) respectively.

###### 

The effect of *ApoAV*-1131T\>C genotype in pregnancy:

  Measurement                               TT (n = 436)             TC (n = 47)\*            P Value
  ----------------------------------------- ------------------------ ------------------------ ---------
  Age (Years)                               30.32 (29.83 -- 30.80)   32.21 (29.74 -- 32.69)   0.26
  Weight (kg)                               74.64 (73.62 -- 75.86)   78.34 (74.64 -- 82.04)   0.06
  Height (cm)                               164.9 (164.3 -- 165.5)   167.0 (165.2 -- 168.8)   0.03
  Head Circumference (cm)                   55.7 (55.6 -- 55.9)      56.0 (55.6 -- 56.4)      0.34
  Arm Circumference (cm)                    28.8 (28.5 -- 29.1)      29.9 (28.2 -- 30.2)      0.49
  Bicep (cm)                                11.1 (10.7 -- 11.5)      11.8 (10.5 -- 13.3)      0.33
  Triceps (cm)                              21.7 (21.0 -- 22.3)      21.6 (19.6 -- 23.6)      0.97
  Sub Scapular (cm)                         21.9 (21.1 -- 22.7)      23.1 (20.6 -- 25.5)      0.39
  \% Body Fat                               32.47 (32.00 -- 32.93)   33.14 (31.71 -- 34.56)   0.38
  Sum Skin fold (cm)                        52.5 (50.8 -- 54.2)      54.7 (49.7 -- 60.4)      0.43
  Body Density                              1.026 (1.025 -- 1.027)   1.024 (1.021 -- 1.027)   0.20
  Fasting Glucose (mmol/l)                  4.35 (4.31 -- 4.38)      4.43 (4.33 -- 4.53)      0.13
  Fasting Total Cholesterol (mmol/l)        6.43 (6.31 -- 6.53)      6.75 (6.40 -- 7.11)      0.08
  Fasting Triglycerides (mmol/l)            1.98 (1.92 -- 2.04)      2.2 (2.01 -- 2.42)       0.04
  Fasting HDL-C (mmol/l)                    1.98 (1.94 -- 2.03)      2.07 (1.94 -- 2.20)      0.20
  Fasting LDL-C (mmol/l)                    3.43 (3.33 -- 3.53)      3.56 (3.25 -- 3.89)      0.44
  Fasting Total Cholesterol/Fasting HDL-C   3.33 (3.25 -- 3.41)      3.3 (3.06 -- 3.56)       0.85
  Fasting HDL-C/Fasting LDL-C Ratio         0.48 (0.46 -- 0.50)      0.5 (0.44 -- 0.56)       0.67

\*No rare homozygous subjects were identified

###### 

The effect of *ApoAV*S19W genotype in pregnancy:

  Measurement                               SS (n = 400)             SW/WW (n = 62)\*         P Value
  ----------------------------------------- ------------------------ ------------------------ ---------
  Age (Years)                               30.38 (29.87 -- 30.89)   30.1 (29.80 -- 32.39)    0.31
  Weight (kg)                               75.51 (74.30 -- 76.74)   73.11 (70.15 -- 76.21)   0.15
  Height (cm)                               165.2 (164.6 -- 165.8)   164.3 (162.8 -- 165.9)   0.31
  Head Circumference (cm)                   55.9 (55.7 -- 56.0)      55.6 (55.3 -- 56.0)      0.44
  Arm Circumference (cm)                    28.9 (28.6 -- 29.3)      28.6 (27.7 -- 29.4)      0.42
  Bicep (cm)                                11.2 (10.7 -- 11.8)      11.1 (10.0 -- 12.4)      0.92
  Triceps (cm)                              21.9 (21.2 -- 22.5)      21.5 (19.7 -- 23.2)      0.71
  Sub Scapular (cm)                         22.3 (21.4 -- 23.1)      21.2 (19.0 -- 23.3)      0.35
  \% Body Fat                               32.65 (32.16 -- 33.14)   32.29 (31.05 -- 33.54)   0.61
  Sum Skin fold (cm)                        53.1 (51.3 -- 55.0)      51.8 (47.5 -- 56.5)      0.60
  Body Density                              1.026 (1.025 -- 1.027)   1.026 (1.024 -- 1.029)   0.79
  Fasting Glucose (mmol/l)                  4.36 (4.32 -- 4.39)      4.39 (4.30 -- 4.48)      0.50
  Fasting Total Cholesterol (mmol/l)        6.37 (6.27 -- 6.49)      6.73 (6.44 -- 7.05)      0.03
  Fasting Triglycerides (mmol/l)            1.97 (1.91 -- 2.03)      2.29 (2.12 -- 2.48)      \<0.001
  Fasting HDL-C (mmol/l)                    1.97 (1.92 -- 2.01)      2.06 (1.95 -- 2.17)      0.11
  Fasting LDL-C (mmol/l)                    3.4 (3.30 -- 3.51)       3.5 (3.24 -- 3.78)       0.53
  Fasting Total Cholesterol/Fasting HDL-C   3.33 (3.24 -- 3.41)      3.35 (3.14 -- 3.58)      0.84
  Fasting HDL-C/Fasting LDL-C Ratio         0.48 (0.46 -- 0.50)      0.48 (0.43 -- 0.54)      0.97

\*Includes one rare homozygous subject

Total Cholesterol concentrations were raised in pregnant females carrying at least 1 rare allele. Subjects with -1131C allele had 6.75 mmol/l (6.40 -- 7.11) compared to 6.43 mmol/l (6.31 -- 6.53) in non carriers (p = 0.078). Subjects with 19W had 6.73 mmol/l (6.44 -- 7.05) compared to 6.37 mmol/l (6.27 -- 6.49) in non carriers (p = 0.025). The effect of the -1131T\>C variant did not reach significance. There is no evidence of an effect in any of the remaining biochemistry concentrations for either of the polymorphisms.

Subjects carrying at least one rare allele at -1131T\>C were 3.7 kg heavier (p = 0.06) and 2.10 cm taller (p = 0.029) than non carriers. There was no evidence for either genotype altering other anthropometric measures.

Triglyceride Concentrations in mothers and fetal growth
-------------------------------------------------------

Table [3](#T3){ref-type="table"} shows the effect of maternal *ApoAV*-1131T\>C genotype on measures of fetal growth in 483 newborns. There is evidence that maternal genotype alters fetal birth length (from 50.2 cm (50.0 -- 50.4) to 50.9 cm (50.3 -- 51.4), p = 0.022) and birth crown-rump length (from 34.0 cm (33.8 -- 34.1) to 34.5 cm (34.1 -- 35.0), p = 0.02). There was no evidence that maternal genotype alters other fetal growth measurements.

###### 

The effect of -1131T\>C maternal genotype on Fetal Growth:

  Measurement                      TT (n = 436)                  TC (n = 47)\*                  P Value
  -------------------------------- ----------------------------- ------------------------------ ---------
  Gestational Age (weeks)          40.11 (39.98 -- 40.23)        40.26 (39.88 -- 40.64)         0.45
  Corrected Birth weight (grams)   3518.1 (3475.70 -- 3560.49)   3589.65 (3460.77 -- 3718.54)   0.3
  Raw Birth weight (grams)         3535.6 (3493.01 -- 3578.19)   3606.42 (3476.95 -- 3735.88)   0.31
  Birth Length (cm)                50.2 (50.0 -- 50.4)           50.9 (50.3 -- 51.4)            0.02
  Birth Crown Rump Length (cm)     34.0 (33.8 -- 34.1)           34.5 (34.1 -- 35.0)            0.02
  Birth Head Circumference (cm)    35.3 (35.1 -- 35.4)           35.3 (35.0 -- 35.7)            0.72
  Birth Arm Circumference (cm)     11.1 (11.0 -- 11.2)           11.2 (10.9 -- 11.4)            0.66
  Birth Triceps (cm)               4.8 (4.7 -- 4.9)              4.9 (4.6 -- 5.3)               0.54
  Birth Sub Scapular (cm)          4.9 (4.8 -- 5.1)              4.9 (4.6 -- 5.3)               0.95

\*No rare homozygotes were identified

Table [4](#T4){ref-type="table"} shows the effect of the maternal S19W genotype on measures of fetal growth. There is no evidence of an effect on any of the fetal growth measurements.

###### 

The effect of S19W maternal genotype on Fetal Growth:

  Measurement                      SS (n = 400)                   SW/WW (n = 62)\*                P Value
  -------------------------------- ------------------------------ ------------------------------- ---------
  Gestational Age (weeks)          40.11 (39.98 -- 40.24)         40.19 (39.87 -- 40.51)          0.66
  Corrected Birth weight (grams)   3532.26 (3487.51 -- 3577.02)   3504.533 (3391.55 -- 3617.52)   0.65
  Raw Birth weight (grams)         3550.36 (3505.43 -- 3595.30)   3523.99 (3410.55 -- 3637.42)    0.67
  Birth Length (cm)                50.3 (50.1 -- 50.5)            50.1 (49.6 -- 50.6)             0.39
  Birth Crown Rump Length (cm)     34.1 (33.9 -- 34.2)            33.9 (33.5 -- 34.3)             0.51
  Birth Head Circumference (cm)    35.3 (35.1 -- 35.7)            35.3 (35.0 -- 35.6)             0.90
  Birth Arm Circumference (cm)     11.1 (11.0 -- 11.2)            11.1 (10.9 -- 11.4)             0.77
  Birth Triceps (cm)               4.8 (4.7 -- 4.9)               4.9 (4.6 -- 5.2)                0.46
  Birth Sub Scapular (cm)          4.1 (4.8 -- 5.0)               5.2 (4.9 -- 5.5)                0.08

\*Includes one rare homozygous subject

Discussion
==========

We have shown that variation in the *ApoAV*gene alters triglyceride concentrations in pregnancy. The two haplotypes, defined in this study by the -1131T\>C and S19W SNPs, raise triglycerides by 11.0% (1.5% -- 22.2%) and 16.2% (7.6% -- 25.9%) respectively. The -1131T\>C and S19W alleles were previously shown to increase triglyceride concentrations in non-pregnant caucasian females by 22.0% \[[@B11]\]. The -1131T\>C variant therefore has a slightly lower magnitude of effect on triglycerides in pregnancy as it does outside pregnancy, although based on our 95% confidence intervals we cannot exclude an effect as small as 1.5% or as large as 22.2% for -1131T\>C variant and as small as 7.6% and 25.9% for the S19W variant. Women carrying at least one of either the 19W or -1131C alleles may therefore be at increased risk of complications from raised triglycerides in pregnancy. Further studies are needed to assess this as the size of the increase is modest and the prevalence of clinical complications associated with hypertriglyceridaemia in pregnancy rare.

Evidence so far indicates that the effect of *ApoAV*variants on altering triglyceride concentrations is not lost or reduced in hyperlipidaemic states. In addition to our results in pregnancy, the -1131C allele was analysed in a variety of dyslipidaemic conditions including hyperlipidaemia, hypoalphalipoproteinaemia and hyperalphalipoproteinaemia from the University of California, San Francisco (UCSF) Genomic Resource in Arteriosclerosis and increased triglyceride and VLDL-Cholesterol concentrations by 10.7% and 24.2% respectively and marginally reduced HDL-Cholesterol concentration by 4.9% \[[@B7]\]. The -1131C allele was increased in frequency in hyperlipidaemia vs. control (13%) \[[@B7]\]. There was however no evidence of an allelic association with either hypoalphalipoproteinaemia or hyperalphalipoproteinaemia \[[@B7]\].

Both of the variants investigated may have different functional properties. The -1131T\>C variant is in the promoter region and is in linkage disequilibrium with a -3A\>G variant that is found in the \'kozak\' region \[[@B13]\]. This -3A\>G variant disrupts a 6 to 8 bp sequence that precedes the initiation methionine and has been previously shown in other genes to severely disrupt ribosomal translation efficiency \[[@B13]\]. The S19W variant is in exon 2 and may cause a variation in the signal sequence which would reduce *ApoAV*secretion across the endoplasmic reticulum which has been previously seen with the ApoB signal peptide variant \[[@B13]\]. As *ApoAV*may act as a brake on the transport of triglyceride rich lipoproteins from the liver, these variants would produce lower levels of *ApoAV*and therefore increase the triglyceride plasma concentrations \[[@B13]\].

Variants in other genes that raise triglycerides are also associated with raised triglycerides in pregnancy. In a study on 250 pregnant Canadian women in their third trimester, the presence of the e4/e4 polymorphism in the *ApoE*gene increased triglyceride concentrations by 0.4 mmol/l (15%) compared to carriers of the e2/e2 variants. Carriers of the S447X polymorphism in the LPL gene showed a decrease of 0.6 mmol/l (21%) (P = 0.003) compared to non-carriers and carriers of the N291S polymorphism showed an increase of 0.5 mmol/l (19%) (P = 0.2) compared to non-carriers \[[@B1]\].

In addition to effects on triglyceride concentrations in pregnancy we examined the role of maternal *ApoAV*genotype on fetal growth. Maternal triglyceride concentration correlates strongly with birth weight and therefore genetic effects on triglyceride concentrations in pregnancy could contribute to fetal growth. We found evidence that the presence of a maternal -1131T\>C variant produces a 0.67 cm (1.3%) increase in birth length (p = 0.022) and a 0.57 cm (1.7%) increase in fetal birth crown to rump length (p = 0.023). However, further studies will be needed to confirm or refute these observations.

Conclusions
===========

In conclusion we have shown that variants in the *ApoAV*gene raise 28-week pregnancy triglyceride concentration, in addition to the triglyceride raising effect of pregnancy itself. Preliminary evidence indicates that the gene is having an effect on fetal growth parameters, but, this needs replicating in further studies

Methods
=======

Subjects
--------

Genotyping was performed on 483 pregnant caucasian females and their partners from the Exeter Family Study of Childhood Health. These samples form part of an ongoing study of parent-offspring trios. Women from the central Exeter area were contacted at 25--26 weeks gestation via letter and recruited via telephone one week later. During the 28^th^week of pregnancy, fasting venous blood samples were taken for biochemical and DNA isolation, as were anthropometric measurements. Informed consent was obtained from all subjects prior to samples and measurements being taken.

A number of fasting blood biochemistries were measured including insulin, glucose, triglycerides, total and HDL-cholesterols, plus LDL-cholesterol (by calculation using the Friedewald formula). All tests were performed in the local Clinical Chemistry laboratory at the Royal Devon and Exeter Hospital using dry slide technology on Vitros 950 analysers (Ortho Clinical) prior to December 2001 and manufacturers\' standard reagents on Modular analysers (Roche) thereafter. All local methods demonstrated analytical Coefficients of Variation (CV\'s) of less than 5%.

Offspring of the mothers had detailed growth measurements at birth, including weight, length, crown/rump length, head circumference, arm circumference, triceps skin fold and sub scapular skin fold. A sample of cord blood was taken at delivery for DNA isolation.

Genotyping
----------

Two *ApoAV*SNPs were used to define the two haplotypes associated with raised triglyceride concentrations. These were -1131T\>C (SNP 3 in \[[@B6]\]) and S19W (c.56C\>G in \[[@B11]\]) which changes a Serine to a Tryptophan amino acid at codon 19 \[[@B11]\].

Restriction Length Fragment Polymorphism (RFLP) analysis was used for both SNPs. The -1131T\>C and S19W SNPs were genotyped as previously described (\[[@B6],[@B11]\] respectively) with the following exceptions:

For -1131T\>C
-------------

The Polymerase Chain Reaction (PCR) was performed in 10 μl volume reactions containing in addition to the standard reagents: 5 M Betaine, 5% DMSO due to the high GC content of the target product, and 0.4 U of Amplitaq Gold (Applied Biosystems, UK).

PCR cycling conditions were: denaturation at 95°C for 12 mins, followed by 40 cycles of denaturation at 95°C for 1 min, annealing at 54°C for 1 min and extension at 72°C for 2 mins, with a final 10 min extension at 72°C.

The PCR was digested using 2 U of MseI (New England Biolabs, UK) and incubated at 37°C overnight. The digested product was run out on a 3% agarose gel for one and a half hours at 200 V.

For S19W
--------

The PCR was performed in a 10 μl volume reaction containing in addition to the standard reagents: 0.4 U of Amplitaq Gold (Applied Biosystems, UK).

PCR cycling conditions were: denaturation at 94°C for 12 mins followed by 34 cycles of denaturation at 94°C for 45 secs, annealing at 65°C for 45 secs and extension at 72°C for 45 secs, with a final extension at 72°C for 10 mins.

The PCR product was digested using 7 U of EagI and incubated at 37°C overnight. The digested product was run out on a 3% agarose gel for one and a half hours at 200 V.

We performed extensive genotype quality control checks, including confirming the presence of any rare homozygotes by re-genotyping and sequencing, scoring gels on two separate occasions and re-genotyping 10% of randomly chosen samples. Overall genotyping results were obtained in 94.5% of the samples and no errors in genotyping were detected.

Statistics
----------

Hardy Weinberg Equilibrium for each SNP was tested by comparing observed genotype numbers with expected genotype numbers based on observed allele frequencies, using a Chi-square analysis.

The LDMAX function of GOLD software was used to calculate the Linkage Disequilibrium (LD) between the two SNPs.

The correlation between maternal triglycerides, HDL-cholesterol, LDL-cholesterol and measures of fetal growth were calculated using regression analysis with SPSS.

The associations between the genotype of each SNP and triglyceride concentrations were performed using univariate general linear model analysis in SPSS. Each genotype was looked at independently and samples that contained at least one copy of the rare allele for the other SNP were not included in the analysis. All non-normally distributed data was log-transformed and back transformed geometric means and 95% Confidence Intervals are quoted.

Maternal anthropometry was uncorrected and maternal biochemistry measures were corrected for weight (with the exception of glucose that was corrected for age and weight due to their significant effect on glucose).

Gestational age was corrected for sex and all other fetal growth measurements were corrected for gestational age and sex.

The comparison between pregnant female and male triglyceride concentrations were determined using an Independent T-Test.
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